Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Kuo

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
The Journal of Antibiotics|June 1, 1992
Anthelmintic activity of dioxapyrrolomycinG A Conder, R J Zielinski, S S Johnson, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminusM S Kuo, M G Bock, R M Freidinger, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 5, 2014
M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamineJ M Witkin, C Overshiner, X Li, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 1999
Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potencyP D Williams, M G Bock, B E Evans, et al.
Journal of Medicinal Chemistry|June 17, 1998
Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridinesI M Bell, J M Erb, R M Freidinger, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2017
Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive <i>N</i>-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of DepressionJ M Witkin, S N Mitchell, K A Wafford, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The Journal of Antibiotics|June 1, 1992
Anthelmintic activity of dioxapyrrolomycinG A Conder, R J Zielinski, S S Johnson, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminusM S Kuo, M G Bock, R M Freidinger, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 5, 2014
M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamineJ M Witkin, C Overshiner, X Li, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 1999
Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potencyP D Williams, M G Bock, B E Evans, et al.
Journal of Medicinal Chemistry|June 17, 1998
Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridinesI M Bell, J M Erb, R M Freidinger, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2017
Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive <i>N</i>-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of DepressionJ M Witkin, S N Mitchell, K A Wafford, et al.
Pageof 3